The presentation of Phase 3 clinical trial data is a critical event for pharmaceutical companies, as it provides investors and stakeholders with insights into the drug's efficacy and safety, which are key determinants of its regulatory approval and commercial success. Positive data could significantly enhance investor confidence in Reviva Pharmaceuticals, potentially leading to an uptick in its stock price in the short term.